Journal
IMMUNOTHERAPY
Volume 10, Issue 10, Pages 861-869Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/imt-2018-0038
Keywords
primary immunodeficiencies; replacement therapy; SCIG; subcutaneous immunoglobulin
Categories
Funding
- Fundacion Alejandra Ortega Lopez, Colombia
- Octapharma, Vienna, Austria
Ask authors/readers for more resources
Aim: Investigate efficacy, safety and quality of life of Gammanorm (R) 16.5% (subcutaneous immunoglobulin [SCIG]) in patients with primary immunodeficiencies (PIDs) and safety and to lesser extent efficacy in autoimmune diseases. Patients & methods: Medical records were extracted from 31 pediatric and 12 adult patients who received SCIG as part of the Personalized Program at University Children's Hospital, Bogota, Colombia. Results: Mean SCIG dose was 28.7 g/month. Serious bacterial infections were observed in 7/33 patients in the PID group, most often bacterial pneumonia (3/33). There were no serious adverse events related to SCIG treatment. Drug-related adverse reactions were reported in 2/43 patients. Conclusion: Self-administration of SCIG provided effective protection, favorable tolerability and improved quality of life in patients with PIDs and autoimmune diseases from Colombia.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available